RG 6125

Drug Profile

RG 6125

Alternative Names: RG6125; SDP-051

Latest Information Update: 16 May 2016

Price : $50

At a glance

  • Originator Adheron Therapeutics
  • Class Antifibrotics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Osteoblast cadherin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Rheumatoid arthritis
  • Preclinical Cancer; Non-alcoholic steatohepatitis
  • No development reported Fibrosis

Most Recent Events

  • 16 May 2016 No development reported - Phase-I for Fibrosis (In volunteers) in USA (Parenteral)
  • 24 Nov 2015 Adheron plans a phase II trial for Rheumatoid arthritis in USA
  • 09 Oct 2015 Roche acquires SDP 051 from Adheron Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top